Concert Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, revenue was USD 0.029 million compared to USD 32.57 million a year ago. Net loss was USD 90.18 million compared to USD 43.92 million a year ago. Basic loss per share from continuing operations was USD 2.13 compared to USD 1.29 a year ago. Diluted loss per share from continuing operations was USD 2.13 compared to USD 1.29 a year ago.